Hoyle Cohen, LLC Viracta Therapeutics, Inc. Transaction History
Hoyle Cohen, LLC
- $1.31 Billion
- Q2 2024
A detailed history of Hoyle Cohen, LLC transactions in Viracta Therapeutics, Inc. stock. As of the latest transaction made, Hoyle Cohen, LLC holds 14,000 shares of VIRX stock, worth $140. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14,000
Previous 14,000
-0.0%
Holding current value
$140
Previous $14,000
50.0%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding VIRX
# of Institutions
41Shares Held
5.64MCall Options Held
0Put Options Held
0-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.52MShares$15,2020.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA954KShares$9,5440.0% of portfolio
-
Samsara Bio Capital, LLC Palo Alto, CA690KShares$6,8970.09% of portfolio
-
Stonepine Capital Management, LLC Bend, OR500KShares$5,0000.07% of portfolio
-
Laurion Capital Management LP New York, NY332KShares$3,3210.0% of portfolio
About Viracta Therapeutics, Inc.
- Ticker VIRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,558,200
- Market Cap $376K
- Description
- Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket tr...